Year 2020, Volume 9 , Issue 2, Pages 222 - 231 2020-06-30

Covid-19’un Klinik Yönetimi ve Hemşirelik
Clinical Management and Nursing of COVID-19

Hatice DEMİRAĞ [1] , Sevilay HİNTİSTAN [2]


“COVID-19” hastalığı, Dünya Sağlık Örgütü (DSÖ) tarafından 11 Mart 2020 tarihinde pandemi olarak ilan edilen ve ciddi akut solunum sendromu koronavirüs 2'nin (SARS-CoV-2) neden olduğu bulaşıcı bir hastalıktır. Dünya genelinde hızla yayılan COVID-19 salgını her geçen gün morbitide ve mortalite sayısının artmasına neden olmaktadır. Hasta ile en çok temas eden hemşireler, hastalığın klinik yönetiminde ve enfeksiyonun önlenmesinde önemli derecede rol almaktadırlar. Bu derlemenin amacı, COVID-19’un risk faktörleri, bulaş yolu, tanı, tedavi hakkında bilgi vermek, klinik semptomları tanımlamak ve COVID-19 enfeksiyonu ile hastaneye başvuran hastaların klinik yönetiminde optimum hemşirelik yönetimini tartışmaktır.

“COVID-19” disease is an infectious disease that was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 epidemic, which is spreading worldwide, causes morbidity and mortality increase day by day. Nurses who have the most contact with the patient play an important role in clinical management of the disease and prevention of infection. The purpose of this review is to provide information about the risk factors, transmission route, diagnosis and treatment of COVID-19, to identify clinical symptoms, and to discuss optimal nursing management in the clinical management of patients admitted to the hospital with COVID-19 infection.

  • 1. Tomasi DL. Coronavirus disease (COVID-19). A socioepidemiological analysis. Bennington, VAAT: Vermont Academy of Arts and Sciences LV(I), 2020; (1): p.1-5. https://www.researchgate.net/publication/339936638.
  • 2. Salute MD. Nuovo Coronavirus. Roma, I: Governo-Repubblica Italiana, 2020. http://www.salute.gov.it/nuovocoronavirus. (Erişim Tarihi: 26.03.2020).
  • 3. De Rio C, Malani PN. Novel Coronavirus-Important Information for Clinicians. JAMA, 2020; 323(11): 1039-40. doi:10.1001/jama.2020.1490.
  • 4. World Health Organization (WHO). Q&A on coronaviruses, 2020. https://www.who.int/health-topics/coronavirus. (Erişim Tarihi: 26.03.2020).
  • 5. Salute MD. Covid-19 - Situazione in Italia. Roma, I: Governo-Repubblica Italiana, 2020. http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5351&area=nuovoCoronavirus&menu=vuoto. (Erişim Tarihi: 26.03.2020).
  • 6. World Health Organization (WHO). Rolling Updates on Coronavirus Disaesa (COVİD-19), 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. (Erişim Tarihi: 27.03.2020).
  • 7. World Health Organization (WHO). Coronavirus disease (COVID-19) outbreak situation, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (Erişim Tarihi: 02.04.2020).
  • 8. T.C. Sağlık Bakanlığı. Türkiye’deki güncel durum: Türkiye genel koronavirüs tablosu, 2020. https://covid19.saglik.gov.tr/. (Erişim Tarihi: 31.03.2020).
  • 9. Bosely S, Quoting Professor G Leung (Hong Kong). Coronavirus ‘could infect 60% of global population if unchecked’. The Guardian, 2020 Feb 11. https://www.theguardian.com/world/2020/feb/11/coronavirus-expert-warns-infection-could-reach-60-of-worlds-population. (Erişim Tarihi: 30.03.2020).
  • 10. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings, 2020. (https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html). (Erişim Tarihi: 27.03.2020).
  • 11. World Health Organization (WHO). Coronavirus, 2020. https://www.who.int/health-topics/coronavirus#tab=tab_1. (Erişim Tarihi: 27.03.2020).
  • 12. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Who is at risk for severe disease from COVID-19?, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html. (Erişim Tarihi: 27.03.2020).
  • 13. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi, 2020; 41(2): 145-51. DOI:10.3760/cma.j.issn.0254-6450.2020.02.003.
  • 14. Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis, 2020 Feb 28. pii: ciaa201. doi: 10.1093/cid/ciaa201. [Epub ahead of print].
  • 15. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA, 2020 Feb 14. doi: 10.1001/jama.2020.2131. [Epub ahead of print].
  • 16. Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi, 2020 Feb 11; 58(0): E005. doi: 10.3760/cma.j.issn.0578-1310.2020.0005. [Epub ahead of print].
  • 17. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): What Healthcare Personnel Should Know about Caring for Patients with Confirmed or Possible COVID-19 Infection, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/caring-for-patients.html. (Erişim Tarihi: 27.03.2020).
  • 18. Centers for Disease Control and Prevention (CDC). How Coronavirus Spreads, 2020. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. (Erişim Tarihi: 28.03.2020).
  • 19. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020 Feb 28: p.1-13. doi: 10.1056/NEJMoa2002032. [Epub ahead of print].
  • 20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet,2020; 395(10223): 497-506. DOI:https://doi.org/10.1016/S0140-6736(20)30183-5.
  • 21. Wang D, Hu B, Hu C, et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. JAMA,2020; 323(11): 1061-69. doi:10.1001/jama.2020.1585.
  • 22. Chan JF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A Study of a family cluster. The Lancet, 2020; 395(10223): 514-23. DOI: 10.1016/S0140-6736(20)30154-9.
  • 23. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med, 2020; 382: 929-36. doi: 10.1056/NEJMoa2001191.
  • 24. Chen N, Zhou M, Dong X, Qu J, Gong F. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet , 2020; 395(10223): 507-13. DOI: 10.1016/S0140-6736(20)30211-7.
  • 25. Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. New England Journal of Medicine. N Engl J Med, 2020; 382 (13): 1278-80. DOI: 10.1056/NEJMc2001899.
  • 26. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, 2020; 382(13): 1199-207. DOI: 10.1056/NEJMoa2001316.
  • 27. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect, 2020; 9(1): 469-73. DOI: 10.1080/22221751.2020.1732837.
  • 28. Chang D, Minggui L, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan China. JAMA, 2020; 323(11):1092-93. doi:10.1001/jama.2020.1623.
  • 29. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020; 382(8): 727-33. doi: 10.1056/NEJMoa2001017.
  • 30. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med, 2020 ;382(9): 872-4. doi: 10.1056/NEJMc2001272.
  • 31. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology, 2020; 295(1): 18. doi: 10.1148/radiol.2020200236.020 Feb 20: 200463. doi: 10.1148/radiol.2020200463. [Epub ahead of print].
  • 33. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging, 2020 Feb 28. doi: 10.1007/s00259-020-04735-9. [Epub ahead of print].
  • 34. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect, 2020; 80(4): 388-93. doi: 10.1016/j.jinf.2020.02.016.
  • 35. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology; 2020 Feb 26: 200642. doi: 10.1148/radiol.2020200642. [Epub ahead of print].
  • 36. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020; 20: 425–34. doi: 10.1016/S1473-3099(20)30086-4.
  • 37. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med, 2020; 382(12): 1177-9. doi: 10.1056/NEJMc2001737.
  • 38. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging Microbes & Infections, 2020; 9(1): 386-9. doi: 10.1080/22221751.2020.1729071.
  • 39. Young BE, Ong SWX, Kalimuddin S, et al. Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA, 2020 Mar 3. doi: 10.1001/jama.2020.3204. [Epub ahead of print].
  • 40. Zhang Y, Chen C, Zhu S, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19)[J]. China CDC Weekly, 2020; 2(8): 123-4.
  • 41. Xia J, Tong J, Liu M, Shen Y, Gou D. Evaluation of coronavirus tears and conjunctival secretions of patient with SARS-CoV-2 infection. J Med Virol, 2020: p.1-6. https://doi.org/10.1002/jmv.25725.
  • 42. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Highlights of CDC’s Response, 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/summary.html#anchor_1582494216224. (Erişim Tarihi: 29.03.2020).
  • 43. Yu L, Wu S, Hao X, et.al. Rapid colorimetric detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform: iLACO. MedRxiv, 2020 February 24. doi: https://doi.org/10.1101/2020.02.20.20025874. [Epub ahead of print].
  • 44. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19), 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. (Erişim Tarihi: 29.03.2020).
  • 45. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19), 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. (Erişim Tarihi: 29.03.2020).
  • 46. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Information for Clinicians on Therapeutic Options for COVID-19 Patients, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. (Erişim Tarihi: 29.03.2020).
  • 47. Wang M, Cao R, Zhang L, et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020; 30(3): 269-71. doi: 10.1038/s41422-020-0282-0.
  • 48. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 2020; 9(396): 1-10. DOI: 10.1126/scitranslmed.aal3653.
  • 49. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communıcatıon, 2020; 11(1): 222. https://doi.org/10.1038/s41467-019-13940-6.
  • 50. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents, 2020 Mar 4:105932. doi: 10.1016/j.ijantimicag.2020.105932. [Epub ahead of print].
  • 51. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2020 Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237. [Epub ahead of print].
  • 52. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 2020 March 18: 1-13. doi: 10.1056/NEJMoa2001282. [Epub ahead of print].
  • 53. World Health Organization (WHO). Coronavirus disease (COVID-19) advice for the public: When and how to use masks, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks. (Erişim Tarihi: 02.04.2020).
  • 54. Millar RC. Journal of Evidence-based Nursing Practice. J Evidence-based Nurs Prac, 2020; 1(1): 4-8.
  • 55. Centers for Disease Control and Prevention (CDC). Environmental Infection Control Guidelines. Ventilation Specifications: Table B.3. Pressure relationships and ventilation of certain areas of nursing facilities, 2020. https://www.cdc.gov/infectioncontrol/guidelines/environmental/appendix/air.html#tableb3. (Erişim Tarihi: 30.03.2020).
  • 56. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020; 579:265-9. https://doi.org/10.1038/s41586-020-2008-3.
  • 57. Li J for Quartz. China is being accused of mistreating coronavirus nurses for propaganda, 2020. https://qz.com/1804040/chinas-coverage-of-coronavirus-nurses-provokes-backlash/. (Erişim Tarihi: 01.04.2020).
Primary Language tr
Subjects Health Care Sciences and Services
Journal Section Derlemeler
Authors

Orcid: 0000-0002-2393-563X
Author: Hatice DEMİRAĞ (Primary Author)
Institution: GÜMÜŞHANE ÜNİVERSİTESİ, KELKİT SAĞLIK HİZMETLERİ MESLEK YÜKSEKOKULU
Country: Turkey


Orcid: 0000-0002-5907-5723
Author: Sevilay HİNTİSTAN
Institution: KARADENİZ TEKNİK ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ FAKÜLTESİ, HEMŞİRELİK BÖLÜMÜ, İÇ HASTALIKLARI HEMŞİRELİĞİ ANABİLİM DALI
Country: Turkey


Dates

Publication Date : June 30, 2020

Bibtex @review { gumussagbil727393, journal = {Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi}, issn = {}, eissn = {2146-9954}, address = {}, publisher = {Gumushane University}, year = {2020}, volume = {9}, pages = {222 - 231}, doi = {10.37989/gumussagbil.727393}, title = {Covid-19’un Klinik Yönetimi ve Hemşirelik}, key = {cite}, author = {Demi̇rağ, Hatice and Hi̇nti̇stan, Sevilay} }
APA Demi̇rağ, H , Hi̇nti̇stan, S . (2020). Covid-19’un Klinik Yönetimi ve Hemşirelik . Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi , 9 (2) , 222-231 . DOI: 10.37989/gumussagbil.727393
MLA Demi̇rağ, H , Hi̇nti̇stan, S . "Covid-19’un Klinik Yönetimi ve Hemşirelik" . Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 9 (2020 ): 222-231 <https://dergipark.org.tr/en/pub/gumussagbil/issue/55123/727393>
Chicago Demi̇rağ, H , Hi̇nti̇stan, S . "Covid-19’un Klinik Yönetimi ve Hemşirelik". Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 9 (2020 ): 222-231
RIS TY - JOUR T1 - Covid-19’un Klinik Yönetimi ve Hemşirelik AU - Hatice Demi̇rağ , Sevilay Hi̇nti̇stan Y1 - 2020 PY - 2020 N1 - doi: 10.37989/gumussagbil.727393 DO - 10.37989/gumussagbil.727393 T2 - Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi JF - Journal JO - JOR SP - 222 EP - 231 VL - 9 IS - 2 SN - -2146-9954 M3 - doi: 10.37989/gumussagbil.727393 UR - https://doi.org/10.37989/gumussagbil.727393 Y2 - 2020 ER -
EndNote %0 Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi Covid-19’un Klinik Yönetimi ve Hemşirelik %A Hatice Demi̇rağ , Sevilay Hi̇nti̇stan %T Covid-19’un Klinik Yönetimi ve Hemşirelik %D 2020 %J Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi %P -2146-9954 %V 9 %N 2 %R doi: 10.37989/gumussagbil.727393 %U 10.37989/gumussagbil.727393
ISNAD Demi̇rağ, Hatice , Hi̇nti̇stan, Sevilay . "Covid-19’un Klinik Yönetimi ve Hemşirelik". Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 9 / 2 (June 2020): 222-231 . https://doi.org/10.37989/gumussagbil.727393
AMA Demi̇rağ H , Hi̇nti̇stan S . Covid-19’un Klinik Yönetimi ve Hemşirelik. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2020; 9(2): 222-231.
Vancouver Demi̇rağ H , Hi̇nti̇stan S . Covid-19’un Klinik Yönetimi ve Hemşirelik. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. 2020; 9(2): 222-231.